title: Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.
abstract: Temozolomide is the current standard of therapy for postoperative patients with glioblastoma starting adjuvant radiotherapy. Hematologic adverse events are the most frequent side effects of temozolomide, while liver toxicity has been reported only in the post-marketing period. Here we report a case of severe temozolomide-induced liver injury during concurrent radiotherapy treatment, at a dose level of 75 mg/m2. The aim of this case report is to focus on the problems of temozolomide-induced hepatotoxicity. In conclusion, a close monitoring of liver function tests is recommended during treatment with temozolomide.
authors: From the Institute of Internal Medicine, Catholic University of Rome (AG, MB, LM); Institute of Radiotherapy, Catholic University of Rome (MAT, BD, NDN, NB); and Institute of Pathology, Catholic University of Rome (FMV).
authors: Antonio
authors: A
authors: Grieco
authors: Maria Antonietta
authors: MA
authors: Tafuri
authors: Marco
authors: M
authors: Biolato
authors: Barbara
authors: B
authors: Diletto
authors: Nicola
authors: N
authors: Di Napoli
authors: Nicola
authors: N
authors: Balducci
authors: Fabio Maria
authors: FM
authors: Vecchio
authors: Luca
authors: L
authors: Miele
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology*; D002779:Cholestasis / Q000139:chemically induced*; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017809:Fatal Outcome; D005909:Glioblastoma / Q000188:drug therapy; D006801:Humans; D008297:Male; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide